Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: A systematic review with statistical meta-analysis

Histopathology

Volumn 52, Issue 3, 2008, Pages 267-276

  Heatley, M K ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Gastric carcinoma; Immunohistochemistry; Meta analysis; Ovarian carcinoma; Systematic review

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BETA CATENIN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; MUCIN 2; SMAD4 PROTEIN; TRANSCRIPTION FACTOR CDX2; VILLIN;

ANTIGEN EXPRESSION; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; SYSTEMATIC REVIEW;

ADENOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; DATABASES, BIBLIOGRAPHIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KERATIN-20; KERATIN-7; OVARIAN NEOPLASMS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 38849182653     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02824.x     Document Type: Review

References (125)

1. Baker PM, Oliva E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int. J. Gynecol. Pathol. 2005 24 39 55.
2. McCluggage WG. Review. Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int. J. Gynecol. Pathol. 2006 25 101 120.
3. Heatley MK. Immunohistochemical and functional biomarkers of value in female genital tract lesions, a systematic review with statistical meta analysis. Int. J. Gynecol. Pathol. 2007 26 177 179.
4. Kiyokawa T, Hamada T, Nikaido T, Yamato A, Okuyama M, Hano H. Ovarian involvement in extragenital neoplasias. Mod. Pathol. 2006 19 98A.
5. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod. Pathol. 1996 9 426 429.
6. Cathro HP, Stoler MH, Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am. J. Clin. Pathol. 2002 117 944 951.
7. Chou Y-C, Chen Y-J, Lai C-R, Wang P-H, Hsin-Chan YC-C. Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006 124 101 105.
8. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 2000 13 962 972.
9. DeCostanzo DC, Elias JM, Chumas JC. Necrosis in 84 ovarian carcinomas: a morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen. Int. J. Gynecol. Pathol. 1997 16 245 249.
10. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin. Cancer Res. 2005 11 3766 3772.
11. Dionigi A, Facco C, Tibiletti MG, Brenasconi B, Riva C, Capella C. Ovarian metastases from colorectal carcinoma: clinicopathologic profile, immunophenotype, and karyotype analysis. Am. J. Clin. Pathol. 2000 11 111 122.
12. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int. J. Gynecol. Pathol. 2002 21 391 400.
13. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJLM. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J. Clin. Pathol. 1999 52 283 290.
14. Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod. Pathol. 1996 9 1040 1044.
15. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl. Immunohistochem. Mol. Morphol. 2005 13 55 60.
16. Moll R, Pitz S, Levy R, Weikel W, Franke WW, Czernobilsky B. Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinomas. Hum. Pathol. 1991 22 989 1001.
17. Multhaupt HAB, Arena-Elliot P, Warhol MJ. Comparison of glycoprotein expression between ovarian and colon adenocarcinomas. Arch. Pathol. Lab. Med. 1999 123 909 916.
18. Torenbeek R, Lagendijk JH, Van Diest PJ, Bril H, Van De Molengraft FJJM, Meijer CJLM. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998 32 20 27.
19. Wauters CCAP, Smedts F, Gerrits LGM, Bosman FT, Ramaekers FCS. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum. Pathol. 1995 26 852 855.
20. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am. J. Clin. Pathol. 2001 116 246 252.
21. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 1992 140 427 447.
22. Breitenecker G, Neunteufel W, Bieglmayer C, Kolbl H, Schieder K. Comparison between tissue and serum content of CA 125, CA 19-9, and carcinoembryonic antigen in ovarian tumors. Int. J. Gynecol. Pathol. 1989 8 97 102.
23. Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am. J. Clin. Pathol. 1997 107 12 19.
24. Gitsch G, Kohlberger P, Hanzal E, Kolbl H, Breitemecker G. Immunohistochemical differentiation between ovarian granulosa cell tumors and ovarian carcinomas. Arch. Gynecol. Obstet. 1991 249 173 177.
25. Kabawat SE, Bast RC, Welch WR, et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrial, and clear cell types. Am. J. Clin. Pathol. 1983 79 98 104.
26. Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamoto K, Nagata I. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol. Obstet. Invest. 1999 47 52 57.
27. Lin M, Hanai J, Wada A, Ozaki M, Nasu K, Okamoto S, Matsumoto K. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases. Acta Pathol. Jpn. 1991 41 233 239.
28. Loy TS, Quesenbury JT, Sharp SC. Distribution of CA125 in adenocarcinoma an immunohistochemiacl study of 481 cases. Am. J. Clin. Pathol. 1992 98 175 179.
29. Macdonald F, Bird R, Stokes H, Russell B, Crocker J. Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours. J. Clin. Pathol. 1988 41 260 264.
30. Neunteufel W, Breitenecker G. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. Gynecol. Oncol. 1989 32 297 302.
31. Tornos C, Soslow C, Chen R, Akram S, Hummer M, Abu-Rustum A, Nadeen A-R, Larry N, Tan LK. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am. J. Surg. Pathol. 2005 29 1482 1489.
32. Charpin C, Bhan AK, Zurawski VR Jr., Scully RE. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies. Int. J. Gynecol. Pathol. 1982 1 231 245.
33. Dabbs DJ, Geisinger KR. Common epithelial ovarian tumors. Immunohistochemical intermediate filament profiles. Cancer 1988 62 368 374.
34. Fleuren GJ, Nap M. Carcinoembryonic antigen in primary and metastatic ovarian tumors. Gynecol. Oncol. 1988 30 407 415.
35. Fowler LJ, Maygarden SJ, Novotny DB. Human alveolar macrophage-56 and carcinoembryonic antigen monoclonal antibodies in the differential diagnosis between primary ovarian and metastatic gastrointestinal carcinomas. Hum. Pathol. 1994 25 666 670.
36. Goldenberg DM, Sharkey RM, Primus FJ. Immunocytochemical detection of carcinoembryonic antigen in conventinal histopathology specimens. Cancer 1978 42 1546 1553.
37. Heald J, Buckley CH, Fox H. An immunohistochemical study of distribution of carcinoembryonic antigen in epithelial tumours of the ovary. J. Clin. Pathol. 1979 32 918 926.
38. Heidl G. Demonstration of carcinoembryonic antigen (CEA) by means of the immunoperoxidase technique in paraffin-embedded specimens of tumor tissues. Exp. Pathol. 1982 21 79 88.
39. Jorgensen A, Nielsen K. Epithelial antigens in carcinomas of the ovaries. Relation to histological classification. APMIS 1994 102 533 537.
40. Khalifa MA, Sesterhenn IA. Tumor markers of epithelial ovarian neoplasms. Int. J. Gynecol. Pathol. 1990 9 217 230.
41. Martinazzi M, Crivelli F, Grassi C, Zampatti C. Immunohistochemical distribution of mucinous-like carcinoma associated antigen (MCA) in breast and non-breast cancer: comparison with other biological parameters. Int. J. Biol. Markers 1990 5 138 144.
42. Savoie SC, Sikorska HM. Immunohistochemical characterization of a new anticarcinoembryonic antigen monoclonal antibody. Anticancer Res. 1991 11 1 12.
43. Sheahan K, O'Brien MJ, Burke B, Dervan PA, O'Keane JC, Gottlieb LS, Zamcheck N. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am. J. Clin. Pathol. 1990 94 157 164.
44. Tohya T, Iwamasa T, Maeyama M. Biochemical and immunohistochemical studies on carcinoembryonic antigen of ovarian mucinous and serous tumors. Gynecol. Oncol. 1986 23 291 303.
45. Fraggetta F, Pelosi G, Cafici A, Scollo P, Nuciforo P, Viale G. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch. 2003 443 782 786.
46. Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod. Pathol. 2004 17 1392 1399.
47. Kim MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J. Korean Med. Sci. 2005 20 643 648.
48. Logani S, Oliva E, Arnell PM, Amin MB, Young RH. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod. Pathol. 2005 18 19 25.
49. Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF Jr. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod. Pathol. 2003 16 913 919.
50. Tornillo L, Moch H, Diener P-A, Lugli A, Singer G. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J. Clin. Pathol. 2004 57 641 643.
51. Reis-Filho JS, Simpson PT, Fulford LG, Martins A, Schmitt FC. P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. Pathol. Res. Pract. 2003 199 785 793.
52. Bacchi CE, Gown AM. Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffin-embedded tissue. Lab. Invest. 1991 64 418 424.
53. Moll R, Robine S, Dudouet B, Louvard D. Villin: a cytoskeletal protein and a differentiation marker expressed in some human adenocarcinomas. Virchows Arch. B. Cell Pathol. 1987 54 155 169.
54. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum. Pathol. 2000 31 672 677.
55. Devine PL, McGuckin MA, Birrell GW, Whitehead RH, Sachdev GP, Shield P, Ward BG. Monoclonal antibodies reacting with the MUC2 mucin core protein. Br. J. Cancer 1993 67 1182 1188.
56. Wang R-Q, Fang D-C. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J. Clin. Pathol. 2003 56 378 384.
57. Dong Y, Walsh MD, Cummings MC, Wright RG, Soo Keat Khoo SK, Parsons PG, McGuckin MA. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J. Pathol. 1997 183 311 317.
58. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J. Clin. Oncol. 2002 32 525 529.
59. Hanski C, Hofmeier M, Schmitt-Graff A, Riede E, Hanski ML, Borchard F, Sieber E, Niedobitek F, Foss HD, Stein H, Riecken EO. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J. Pathol. 1997 182 385 391.
60. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993 53 641 651.
61. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum. Pathol. 2002 33 1175 1181.
62. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG. Expression of alpha-Methylacyl-CoA Racemose (P504S) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum. Pathol. 2003 34 792 796.
63. Chu PG, Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am. J. Clin. Pathol. 2004 121 884 892.
64. Driesen A, Nafteux P, Lerut T, Van Raemdonck D, De Leyn P, Filez L, Penninckx F, Geboes K, Ectors N. Identical cytokeratin expression CK7+/CK20- in esophageal and cardiac cancer. Mod. Pathol. 2004 17 49 55.
65. Flucke U, Steinborn E, Dries V, Monig SP, Schneider PM, Thiele J, Holscher AH, Dienes HP, Baldus SE. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology 2003 43 127 134.
66. Gurbuz Y, Kose N. Cytokeratin expression patterns of gastric carcinomas according to Lauren and Goseki classification. Appl. Immunohistochem. Mol. Morphol. 2006 14 303 308.
67. Kim MA, Lee HS, Yang H-K, Kim WH. Cytokeratin expression profile in gastric carcinomas. Hum. Pathol. 2004 35 576 581.
68. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod. Pathol. 2003 16 403 410.
69. Oconnel FP. Utility of immunohistochemistry in distinguishing primary adenocarcinoma from metastatic breast carcinomas in the gastrointestinal tract. Arch. Pathol. Lab. Med. 2005 129 338 347.
70. Ormsby AH, Goldblum JR, Rice TW, Richter JE, Gramlich TL. The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology 2001 38 307 311.
71. Osborn M, Mazzoleni G, Santini D, Marrano D, Martinelli G, Weber K. Villin, intestinal brush border hydrolases and keratin polypeptides in intestinal metaplasia and gastric cancer; an immunohistologic study emphasizing the different degrees of intestinal and gastric differentiation in signet ring cell carcinomas. Virchows Arch. Pathol. Anat. Histopathol. 1988 413 303 312.
72. Park SY, Kim HS, Hong EK, Kim WH, Park SY, Kim HS, Hong EK, Kim WH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum. Pathol. 2002 33 1078 1085
73. Shen B, Ormsby AH, Shen C, Dumot JA, Shao Y-W, Bevins CL, Gramlich TL. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction. Cancer 2002 94 820 831.
74. Taniere P. Cytokeratin expression in adenocarcinomas of the esophagastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am. J. Surg. Pathol. 2002 26 1213 1221.
75. Uozaki H, Chong J-M, Fujimoto E, Itoh M, Saito M, Sakuma K, Sudo M, Ushiku T, Niki T, Nagai H, Takada K, Fukayama M. Soft and hard keratin expression in Epstein-Barr-virus-associated gastric carcinoma. Anticancer Res. 2005 25 3183 3190.
76. van Lier MGF, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJLF. Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J. Clin. Pathol. 2005 58 722 724.
77. Wang NP, Zee S, Zarbo RJ, Bacchi CE, Gown AM. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl. Immunohistochem. Mol. Morphol. 1995 3 99 107.
78. Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial and Merkel cell carcinomas. Mod. Pathol. 1995 8 384 887.
79. Sarbia M, Borchard F, Hengels KJ. Histogenetical investigations on adenocarcinomas of the esophagogastric junction: an immunohistochemical study. Pathol. Res. Pract. 1993 189 530 535.
80. Bhatnagar J, Heroman W, Murphy M, Austin GE. Immunohistochemical detection of carcinoembryonic antigen in esophageal carcinomas: a comparison with other gastrointestinal neoplasms. Anticancer Res. 2002 22 1949 1957.
81. Erkisi M, Doran F, Burgut R, Colakoglu S, Karaer P, Varinli S. Alpha-fetoprotein and carcinoembryonic antigen in gastric carcinoma. J. Exp. Clin. Cancer Res. 1994 13 253 256.
82. Gumzej Z, Cupic H, Brezovecki D, Belicza M. Correlation between new histological grading system of gastric cancer according to Goseki and carcinoembryonic antigen (CEA) expression. Croat. J. Gastroenterol. Hepatol. 1994 3 57 62.
83. Honda T, Tamura G, Endoh Y, Nishizuka S, Kawata S, Motoyama Ti. Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach. Jpn J. Clin. Oncol. 2005 35 580 586.
84. Kim DY, Kim HR, Shim JH, Park CS, Kim SK, Kim YJ. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J. Surg. Oncol. 2000 74 185 192.
85. Kocer B, Soran A, Kiyak G, Erdogan S, Eroglu A, Bozkurt B, Solak C, Cengiz O. Prognostic significance of mucin expression in gastric carcinoma. Dig. Dis. Sci. 2004 49 954 964.
86. Kojima O, Tanioku T, Kitagawa N, et al. Comparative study of CEA staining in gastric and colorectal cancer tissues. Gastroenterol. Jpn. 1984 19 18 23.
87. Lee HS, Choi SI, Lee HK, Kim HS, Yang H-K, Kang GH, Kim YI, Lee BL, Kim WH. Distinct clinical features and outcomes of gastric cancers with microsatellite instability. Mod. Pathol. 2002 15 632 640.
88. Lee HS, Chang MS, Yang H-K, Lee BL, Kim WH. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin. Cancer Res. 2004 10 1698 1705.
89. Nasierowska-Guttmejer A, Szawlowski AW. Immunohistochemical detection of carcinoembryonic antigen (CEA) in non-cancerous and cancerous gastric mucosa. Int. J. Biol. Markers 1989 4 8 12.
90. Ohuchi N, Simpson JF, Colcher D, Schlom J. Complementation of anti-CEA and anti-TAG monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int. J. Cancer 1987 40 726 733.
91. Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolos C, David L. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J. Pathol. 2003 199 36 40.
92. Bai Y-Q, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, Kenji Y, Osmar S, Kiyoshi S, Takeshita K, Iwai T, Yuasa Y. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002 176 47 55
93. Fan Z, Li J, Dong B, Huang X. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin. Cancer Res. 2005 11 6162 6170.
94. Ito R, Oue N, Yoshida K, Kunimitsu K, Nakayama H, Nakachi K, Yasui W. Clinicopathological significant and prognostic influence of cadherin 17 expression in gastric cancer. Virchows Arch. 2005 447 717 722.
95. Kim HS, Lee JS, Freund JN, Min KW, Lee JS, Kim W, Juhng SW, Park CS. CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. J. Gastroenterol. Hepatol. 2000 21 438 442.
96. Mizoshita T, Tsukamoto T, Inada K-I, Ogasawara N, Hirata A, Kato S, Joh T, Itoh M, Yamamura Y, Tatematsu M. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa. Pathol. Int. 2004 54 392 400.
97. Roessler K, Monig S-P, Schneider P-M, Hanisch F-G, Landsberg S, Thiele J, Holscher A-H, Dienes H-P, Baldus S-E. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis. World J. Gastroenterol. 2005 11 3182 3188.
98. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am. J. Surg. Pathol. 2003 27 303 310.
99. Huiping C, Kristjansdottir S, Jonasson JG, Magnusson J, Egilsson V, Ingvarsson S. Alterations of E-cadherin and beta-catenin in gastric cancer. BMC Cancer 2001 1 16.
100. Akashi H, Hinoda Y, Itoh F, Adachi M, Endo T, Imai K. A novel gastric-cancer-associated mucin antigen defined by a monoclonal antibody A3D4. Int. J. Cancer 1997 73 795 801.
101. Akyurek N, Akyol G, Dursun A, Yamac D, Gunel N. Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. Pathol. Res. Pract. 2002 198 665 674.
102. Babu SD, Jayanthi V, Devaraj N, Reis CA, Devaraj H. Expression of mucins (MUC2, MUC5AC, and MUC6) in Helicobacter pylori infected preneoplastic and neoplastic human gastric epithelium. Mol. Cancer 2006 5 10.
103. Baldus SE, Zirbes TK, Engel S, Hanisch F-G, Monig SP, Lorenzen J, Glossmann J, Fromm S, Thiele J, Pichlmaier H, Dienes HP. Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1 and MUC2 with the histopathological subtype and prognosis of gastric carcinomas. Int. J. Cancer 1998 79 133 138.
104. Endoh Y, Tamura G, Motoyama T, Ajioka Y, Watanabe H. Well-differentiated adenocarcinoma mimicking complete-type intestinal metaplasia in the stomach. Hum. Pathol. 1999 30 826 832.
105. Filipe MI, Linehan JM, Durrant LG, Price MR, Smeeton NC, Pathak S, Swallow DM. Expression of a peptide epitope of the colonic mucin MUC2 in precursor lesions to gastric carcinoma. Eur. J. Cancer Prev. 1996 5 287 295.
106. Gurbuz Y, Kahlke V, Kloppel G. How do gastric carcinoma classification systems relate to mucin expression patterns? An immunohistochemical analysis in a series of advanced gastric carcinomas. Virchows Arch. 2002 440 505 511.
107. Gurbuz Y, Kloppel G. Differentiation pathways in duodenal and ampullary carcinomas: a comparative study on mucin and trefoil peptide expression, including gastric and colon carcinomas. Virchows Arch. 2004 444 536 541.
108. Leteurtre E, Zerimech F, Piessen G, Wacrenier A, Leroy X, Copin M-C, Mariette C, Aubert J-P, Porchet N, Buisine M-P. Relationships between mucinous gastric carcinoma, MUC2 expression and survival. World J. Gastroenterol. 2006 12 3324 3331.
109. Machado JC, Nogueira AM, Carneiro F, Reis CA, Sobrinho-Simoes M. Gastric carcinoma exhibits distinct types of cell differentiation: an immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6. J. Pathol. 2000 190 437 443.
110. Mitsuuchi M, Hinoda Y, Itoh F, Endo T, Satoh M, Xing PX, Imai K. Expression of MUC2 gene in gastric regenerative, metaplastic, and neoplastic epithelia. J. Clin. Lab. Anal. 1999 13 259 265.
111. Morohara K, Tajima Y, Nakao K, Nishino N, Aoki S, Kato M, Sakamoto M, Yamazaki K, Kaetsu T, Suzuki S, Tsunoda A, Tachikawa T, Kusano M. Gastric and intestinal phenotypic cell marker expressions in gastric differentiated-type carcinomas: association with E-cadherin expression and chromosomal changes. J. Cancer Res. Clin. Oncol. 2006 132 363 375.
112. Motoshita J, Oue N, Nakayama H, Kuraoka K, Aung PP, Taniyama K, Matsusaki K, Yasui W. DNA methylation profiles of differentiated-type gastric carcinomas with distinct mucin phenotypes. Cancer Sci. 2005 96 474 479.
113. Ohe Y, Hinoda Y, Irimura T, Imai K, Yachi A. Expression of sulfated carbohydrate chains detected by monoclonal antibody 91.9H in human gastric cancer tissues. Jpn J. Cancer Res. 1994 85 400 408.
114. Reis CA, David L, Carvalho F, Mandel U, De Bolos C, Mirgorodskaya E, Clausen H, Sobrinho-Simoes M. Immunohistochemical study of the expression of MUC6 mucin and co-expression of other secreted mucins (MUC5AC and MUC2) in human gastric carcinomas. J. Histochem. Cytochem. 2000 48 377 388.
115. Sakamoto H, Yonezawa S, Utsunomiya T, Tanaka S, Kim YS, Sato E. Mucin antigen expression in gastric carcinomas of young and old adults. Hum. Pathol. 1997 28 1056 1065.
116. Tajima Y, Shimoda T, Nakanishi Y, Yokoyama N, Tanaka T, Shimizu K, Saito T, Kawamura M, Kusano M, Kumagai K. Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil. J. Cancer Res. Clin. Oncol. 2003 129 683 690.
117. Tanaka M, Kitajima Y, Sato S, Miyazaki K. Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy. Br. J. Surg. 2003 90 95 101.
118. Taylor KL, Mall AS, Barnard RA, Ho SB, Cruse JP. Immunohistochemical detection of gastric mucin in normal and disease states. Oncol. Res. 1998 10 465 473.
119. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS, Sato E. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin. Cancer Res. 1998 4 2605 2614.
120. Wu M, Semba S, Li D, Yokozaki H. Molecular pathological analysis of mucinous adenocarcinomas of the stomach. Pathobiology 2004 71 201 210.
121. Van Rees BP, Caspers E, Zur Hausen A, van den Brule A, Drillenberg P, Weterman MAJ, Offerhaus GJA. Different pattern of alleleic loss in Epstein Barr virus positive gastric cancer with emphasis on the p53 tumour suppressor pathway. Am. J. Pathol. 2002 161 1207 1212.
122. Machin D, Campbell M, Fayers P, Pinol A. Sample size tables for clinical studies, 2nd edn. Oxford : Blackwell Science, 1997 40 57.
123. Altman DG, Elbourne D. Commentary. Combining results from several clinical trials. Br. J. Obstet. Gynaecol. 1988 95 1 2.
124. Huque MF. Experiences with meta-analysis in NDA submissions. Proc. Biopharmac. Sect. Am. Stat. Soc. 1988 2 28 33.
125. Novelli MR. Dataset for the histopathological reporting of gastric carcinoma, 2nd edn. London : The Royal College of Pathologists, 2006.